BioMarin Pharmaceutical, Inc. (BMRN)
57.18
-1.26
(-2.16%)
USD |
NASDAQ |
Oct 02, 16:00
57.30
+0.12
(+0.21%)
After-Hours: 20:00
BioMarin Pharmaceutical Gross Profit Margin (Quarterly) : 72.27% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 72.27% |
| March 31, 2026 | 74.38% |
| December 31, 2025 | 68.65% |
| September 30, 2025 | 81.58% |
| June 30, 2025 | 81.28% |
| March 31, 2025 | 79.31% |
| December 31, 2024 | 80.25% |
| September 30, 2024 | 73.94% |
| June 30, 2024 | 79.57% |
| March 31, 2024 | 78.54% |
| December 31, 2023 | 76.67% |
| September 30, 2023 | 76.04% |
| June 30, 2023 | 75.84% |
| March 31, 2023 | 76.01% |
| December 31, 2022 | 72.28% |
| September 30, 2022 | 73.03% |
| June 30, 2022 | 73.72% |
| March 31, 2022 | 74.20% |
| December 31, 2021 | 69.56% |
| September 30, 2021 | 70.87% |
| June 30, 2021 | 71.73% |
| March 31, 2021 | 72.26% |
| December 31, 2020 | 68.59% |
| September 30, 2020 | 56.34% |
| June 30, 2020 | 73.06% |
| Date | Value |
|---|---|
| March 31, 2020 | 74.37% |
| December 31, 2019 | 74.95% |
| September 30, 2019 | 75.11% |
| June 30, 2019 | 76.32% |
| March 31, 2019 | 75.83% |
| December 31, 2018 | 76.56% |
| September 30, 2018 | 77.63% |
| June 30, 2018 | 77.04% |
| March 31, 2018 | 76.40% |
| December 31, 2017 | 75.39% |
| September 30, 2017 | 80.20% |
| June 30, 2017 | 79.80% |
| March 31, 2017 | 80.84% |
| December 31, 2016 | 76.12% |
| September 30, 2016 | 79.05% |
| June 30, 2016 | 82.84% |
| March 31, 2016 | 78.33% |
| December 31, 2015 | 77.65% |
| September 30, 2015 | 81.65% |
| June 30, 2015 | 83.30% |
| March 31, 2015 | 82.89% |
| December 31, 2014 | 79.31% |
| September 30, 2014 | 82.38% |
| June 30, 2014 | 83.28% |
| March 31, 2014 | 84.38% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 76.88% |
| Vertex Pharmaceuticals, Inc. | 85.37% |
| Ascendis Pharma A/S | 90.64% |
| BridgeBio Pharma, Inc. | 93.68% |
| Incyte Corp. | 92.57% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 1.19% |
| Return on Assets | 0.85% |
| Return on Invested Capital | 0.95% |
| Profit Margin (Quarterly) | 4.49% |
| Operating Margin (Quarterly) | 20.52% |
| Return on Net Operating Assets | 1.53% |